ILSI-Biomed Israel

BrainStorm Raises $3.6 M To Launch Phase I/II Trial for ALS.

The recent appointment of Adrian Harel as the CEO of BrainStorm Cell Therapeutics (OTCBB: BCLI) signals the beginning of a new era both for the company and for its new top exec. BrainStorm, after several hurdle-crossing years of pre-clinical testing and validation of its autologous stem cell therapy, is about to become the first Israeli company to reach the clinical trial stage with a differentiated stem cell-based therapy. The company`s Phase I/II trial, expected to begin in the spring,...

Robots back breakthrough surgery.

SpineAssist – an Israeli invention – is revolutionizing delicate spinal surgery. Judy Siegel-Itzkovich spoke to the innovative company’s CEO. Many patients scheduled for a major spinal operation naturally worry that they might find themselves in a wheelchair due to a surgical error, or simple bad luck. While this happens only rarely, it is a possibility. The results of orthopedic surgery are as good as the specialist who performs it – but today, the risk is much reduced. Not only is there...

Vaxil’s TB vaccine successfully passes first stage in animal studies

Nes-Ziona, 8th March, 2011. Vaxil Biotherapeutics Ltd., a clinical stage developer of innovative therapeutic vaccines announced today that MTbuVax, its vaccine against the lethal bacteria Mycobacterium Tuberculosis (MTb) has proven to manifest effective induction of immune response in mice. The studies demonstrated that mice vaccinated with MTbuVax produced potent CD4+ and CD8+ T-cell immunity that specifically proliferated in response to the MTbuVax vaccine. In addition, T-cells from vac...

PROLOR BIOTECH SIGNS EXCLUSIVE LICENSE AGREEMENT WITH YEDA FOR ANTI-OBESITY APPLICATIONS

PROLOR Biotech, Inc., (NYSE Amex: PBTH), announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a variety of peptides and small molecules, including the diab...

Rachel Abramovitz Joins JSBarkats PLLC As The Chair Of The Life Sciences Practice

JSBarkats PLLC ("JSBarkats") announced today that Rachel Abramovitz, an experienced corporate attorney, joined the firm as a partner. Rachel has 15 years experience practicing law, including 10 years experience in the pharmaceutical and biotech industries. In addition to supporting the corporate and Israeli practice groups, Rachel will be leading the life sciences group in the firm. " We are pleased to be able to support our life sciences clients with a full range of legal services including IP,...

Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea

The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds. Foamix Ltd., a clinical-stage specialty pharmaceutical company focused on the development of proprietary dermatological and gynecologic topical products, today announced enrollment of the first patient in a Phase II trial of its Topical Minocycline Foam. The double-blind, placebo controlled dose range finding study aims to ...

Molecular imaging to diagnose, monitor and treat disease

Molecular probes from Israel's Aposense show areas of disease on a cellular level and can even provide a picture that reveals the efficacy of chemotherapy. Israeli biotech company Aposense offers a futuristic way of diagnosing, monitoring and treating disease through molecules designed to detect cell death (apoptosis). While apoptosis is a universal process in cell biology, it plays a role in most medical disorders. Targeting cells undergoing apoptosis, for imaging or delivering therapy, can ...

2P2D Ltd. Announces the Appointment of Tovi Bachar, Former Managing Director of GE Healthcare Israel, as Director and Chairman

TEL AVIV, Israel, Feb. 8, 2011 /PRNewswire/ - 2P2D Ltd., a medical device company developing telemedicine systems for clinical trial management, today announced that it has appointed Mr. Tovi Bachar, former Managing Director of GE Healthcare Israel, as Director and Chairman. Tovi Bachar has completed seven years as Managing Director of GE Healthcare Israel, a subsidiary of GE Medical Systems, a leading diagnostic imaging equipment company. In 2008, Tovi Bachar was awarded the Managing Dir...

Brainsway reports improvements in Australian autism trial

Brainsway Ltd. (TASE:BRIN) reports that interim results of an Australian study showed small but significant improvement in patients with autism or Asperger's syndrome treated with its Deep TMS (transcranial magnetic stimulation) device. The study showed improvement in the Theory of Mind (a designated coil for treating autism) and in social communications. The study conducted at the Monash Alfred Psychiatry Research Centre in Melbourne included 16 healthy adults and 20 patients with autis...

Mazor wins FDA approval for Emerald spine implants

Mazor Robotics Ltd. (TASE:MZOR) has obtained US Food and Drug Administration (FDA) marketing approval for its Emerald spinal implants. The company plans to begin marketing in the second half of 2011. Mazor's share price jumped 11 percent in heavy trading on the news, but fell back to a gain of 7.4 percent in afternoon trading to NIS 10.81, giving a market cap of NIS 204 million. The Emerald spinal implant is inserted by the company's robotic SpineAssist system for minimally invasive sp...